Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



TPP-based mitocans: a potent strategy for anticancer drug design

Author affiliations

Abstract

Cancer is one of the most important problems that endanger human health. The number of cancer patients is increasing rapidly worldwide. Compared with normal cells, cancer cells exhibit abnormal metabolism (abnormal glycolysis and oxidative phosphorylation, high levels of reactive oxygen species, anti-apoptosis, high mitochondrial membrane potential, and so on), and specific targeting of these metabolic abnormalities would be a promising drug design direction. These physiological characteristics are closely related to tumorigenesis and development, which are mainly regulated by mitochondria. Therefore, mitochondria have become important anticancer drug targets, attracting much attention in recent years. In this review, we systematically summarize various mitochondrial anticancer drugs developed, especially mitocans based on triphenylphosphonium (TPP), and discuss the advantages of TPP in endowing mitochondrial targeting function.

Graphical abstract: TPP-based mitocans: a potent strategy for anticancer drug design

Back to tab navigation

Article information


Submitted
10 Dec 2019
Accepted
11 May 2020
First published
03 Jun 2020

RSC Med. Chem., 2020, Advance Article
Article type
Review Article

TPP-based mitocans: a potent strategy for anticancer drug design

J. Wang, J. Li, Y. Xiao, B. Fu and Z. Qin, RSC Med. Chem., 2020, Advance Article , DOI: 10.1039/C9MD00572B

Social activity

Search articles by author

Spotlight

Advertisements